Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07495124 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Start date changed from estimate of Sep 1, 2026 to Sep 16, 2026 Eligibility criteria expanded, about 38 words · Secondary endpoints: details revised at 3 of 3 entries · Site details revised Show 3 more changesShow less
    • Eligibility criteria expanded, about 38 words
    • Secondary endpoints: details revised at 3 of 3 entries
    • Site details revised
  2. Recruitment opened Start date: Oct 1, 2026 to Sep 1, 2026 · Site details revisedv6 Show 2 more changesShow less
    • Start date: Oct 1, 2026 to Sep 1, 2026
    • Site details revised
  3. Start date: Jul 1, 2026 to Oct 1, 2026v5
  4. Start date: May 22, 2026 to Jul 1, 2026v4
  5. Start date: May 1, 2026 to May 22, 2026v3
  6. Start date: Apr 1, 2026 to May 1, 2026v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase II trial studies how well giving the insulin-like growth factor binding protein 2 \[pUMVC3-hIGFBP-2 multi-epitope plasmid deoxyribonucleic acid (DNA) (IGFBP-2)\] vaccine after one dose of carboplatin works to stop ovarian cancer from growing, spreading, or getting worse (progressing) in patients whose cancer recurrence is detected only in the blood (serologic detection) following treatment with platinum chemotherapy. IGFBP-2 is a protein found in ovarian cancer cells. The IGFBP-2 vaccine may help the body build an effective immune response to kill tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It has been shown to activate parts of the immune system that may act against tumors. Giving the IGFBP-2 vaccine after a single dose of carboplatin may be an effective way to stop ovarian cancer from progressing in patients with serologic detection following treatment with platinum chemotherapy.
Trial Details
NCT Number NCT07495124
Lead Sponsor University of Washington
Collaborators: The Wayne D. Kuni and Joan E. Kuni Foundation
Conditions Fallopian Tube Carcinoma, Ovarian Carcinoma, Primary Peritoneal Carcinoma
Enrollment 26 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov